Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1423 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Table of Contents
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded101    
    Comments [Add]    

Recommend this journal

Year : 2004  |  Volume : 46  |  Issue : 1  |  Page : 64-71

Open Labeled, Randomized, Switch-Over Study of Two Fixed Doses (10/15mg) Of Aripiprazole : To Evaluate its Safety And Efficacy in the Treatment of Indian Patients of Schizophrenia.

1 Consultant Psychiatrist, Vidyasagar Institute of Mental Health and Neurosciences, 1, Institutional Area, Nehrunagar, New Delhi - 110 017, India
2 Consultant Psychiatrist, Vidyasagar Institute of Mental Health and Neurosciences, 1, Institutional Area, Nehrunagar, New Delhi -110 017, India
3 Consultant Psychiatrist, B-65 Friends Colony (West), New Delhi - 110 065, India
4 Professor & Head, Department of Psychiatry, G. B. Pant Hospital, New Delhi - 110 002, India
5 Consultant Psychiatrist, Flat No. 102, Sai Vishnu Apartment, Damalguda, 1-2-26, HYDERABAD - 500 029, India
6 Associate Professor, Government Medical College, UDAIPUR - 313 001, India
7 Consultant Psychiatrist, 103-104, First Floor, Samvedna Hospital, Below Karnavati Hospital, Ellisbridge, AHMEDABAD - 380 006, India
8 Department of Clinical Research, Torrent Research Centre, Village Bhat, Gandhinagar, India

Correspondence Address:
A Sarin
Department of Clinical Research, Torrent Research Centre, Village: Bhat, Dist: Gandhinagar - 382 428
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 21206777

Rights and PermissionsRights and Permissions

Aripiprazole is a new anti psychotic with a unique receptor binding profile that combines partial agonistic activity at D2 receptor and 5-HT 1A receptor and potent antagonism at 5-HT 2A receptor. This receptor profile makes it possible for it to act as a dopamine system stabilizer. Based on various short term and long term studies, aripiprazole has been found to be effective in schizophrenia and has no significant adverse effect on QTc prolongation, prolactin, serum lipids, and has a low potential for weight gain. Present study aims to evaluate the efficacy and tolerability of aripiprazole (10-15mg/day) in the treatment of Indian patients of schizophrenia and to see its effect on QTc interval, prolactin levels, serum lipids, plasma sugar and weight gain in these patients. Outpatients with an ongoing/newly diagnosed ICD-10 Schizophrenia (n=136) were randomly assigned to 10 or 15 mg dose of Aripiprazole for a period of six weeks. Clinical response was evaluated by the Positive And Negative Symptoms Scale (PANSS), Clinical Global Impression (CGI) scale and safety was evaluated by observing spontaneously reported adverse events and changes in various laboratory parameters. Switching schizophrenic patients to aripiprazole (10/15 mg) from both conventional and atypical anti-psychotics was safe and well tolerated. Six weeks after switching to aripiprazole, patients showed improvements in PANSS scores (P<0.001), EPS, prolactin levels and weight over the baseline levels. No difference was seen in the 10 or 15mg dose groups. One hospitalization was reported (due to hepatitis E). Common side effects reported were insomnia, somnolence, nausea, vomiting and diarrhea. Aripiprazole is a safe and effective anti psychotic in Indian patients - both in newly diagnosed, as well as, in patients not responding to or intolerant to other available typical and atypical antipsychotics.



Print this article         Email this article